Loading company…
Novo Nordisk is a Danish pharmaceutical company developing medicines for chronic diseases, especially diabetes and obesity.
Novo Nordisk A/S, founded in 1923 in Denmark and headquartered in Bagsværd, develops and produces medicines for chronic diseases, particularly diabetes and obesity. Its products include semaglutide, a GLP-1 receptor agonist, as well as insulin, growth hormone therapies and hemophilia treatments. Ben Illemann is the current CEO. In May 2022 it received an undisclosed investment from Flagship Pioneering. In fiscal year 2023 it reported revenue of USD 33.72 bn and EBITDA of USD 15.95 bn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in